p16(CDKN2) gene polymorphism: Association with histologic subtypes of epithelial ovarian cancer in China

International Journal of Gynecological Cancer

Volumn 18, Issue 1, 2008, Pages 30-35

  Yan, L ^a   Na, W ^a   Shan, K ^a   Xiao Wei, M ^a   Wei, G ^a   Shu Cheng, C ^a  

^a HEBEI MEDICAL UNIVERSITY   (China)

Author keywords

Epithelial ovarian cancer; Haplotype; p16; Single nucleotide polymorphism; Susceptibility

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 2A; PROTEIN P16;

ADULT; AGED; ARTICLE; CHINA; CONTROLLED STUDY; FEMALE; GENE FREQUENCY; GENETIC POLYMORPHISM; GENETIC SUSCEPTIBILITY; GENOTYPE; HAPLOTYPE; HISTOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; OVARY CANCER; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SINGLE NUCLEOTIDE POLYMORPHISM; TUMOR SUPPRESSOR GENE;

3' UNTRANSLATED REGIONS; ADENOCARCINOMA, MUCINOUS; ADULT; AGED; CARCINOMA, ENDOMETRIOID; CASE-CONTROL STUDIES; CHINA; CYCLIN-DEPENDENT KINASE INHIBITOR P16; CYSTADENOCARCINOMA, SEROUS; DISEASE PROGRESSION; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HAPLOTYPES; HUMANS; MIDDLE AGED; OVARIAN NEOPLASMS; POLYMERASE CHAIN REACTION; POLYMORPHISM, SINGLE NUCLEOTIDE;

EID: 38049010087     PISSN: 1048891X     EISSN: 15251438     Source Type: Journal    
DOI: 10.1111/j.1525-1438.2007.00953.x     Document Type: Article

References (28)

1. Cao ZY. Chinese obstetrics and gynecology. Peking : Beijing Publisher, 2004 : 2153.
2. Cobrinik D, Dowdy SF, Hinds PW, Mittnacht S, Weinberg RA. The retinoblastoma protein and the regulation of cell cycling. Trends Biochem Sci 1992 17 : 312 5.
3. Fombonne J, Devouassoux-Shisheboran M, Bouvier R, Droz JP, Benahmed M, Krantic S. Analysis of p16INK4A gene promoter in male germ-cell tumors: identification of a new point mutation. Cancer Detect Prev 2005 29 : 1 7.
4. Child FJ, Scarisbrick JJ, Calonje E, Orchard G, Russell-Jones R, Whittaker SJ. Inactivation of tumor suppressor genes p15(INK4b) and p16(INK4a) in primary cutaneous B cell lymphoma. J Invest Dermatol 2002 118 : 941 8.
5. Nakahara Y, Shintani S, Mihara M, Ueyama Y, Matsumura T. High frequency of homozygous deletion and methylation of p16 (INK4A) gene in oral squamous cell carcinomas. Cancer Lett 2001 163 : 221 8.
6. Hsu LS, Lee HC, Chau GY, Yin PH, Chi CW, Lui WY. Aberrant methylation of EDNRB and p16 genes in hepatocellular carcinoma (HCC) in Taiwan. Oncol Rep 2006 15 : 507 11.
7. Abbaszadegan MR, Raziee HR, Ghafarzadegan K, Shakeri MT, Afsharnezhad S, Ghavamnasiry MR. Aberrant p16 methylation, a possible epigenetic risk factor in familial esophageal squamous cell carcinoma. Int J Gastrointest Cancer 2005 36 : 47 54.
8. Marchini S, Codegoni AM, Bonazzi C, Chiari S, Broggini M. Absence of deletions but frequent loss of expression of p16INK4 in human ovarian tumours. Br J Cancer 1997 76 : 146 9.
9. Dong Y, Walsh MD, McGuckin MA. Increased expression of cyclin-dependent kinase inhibitor 2 (CDKN2A) gene product p16INK4A in ovarian cancer is associated with progression and unfavourable prognosis. Int J Cancer 1997 74 : 57 63.
10. Fujita M, Enomoto T, Haba T et al. Alteration of p16 and p15 genes in common epithelial ovarian tumors. Int J Cancer 1997 74 : 148 55.
11. Langosch KM, Ocon E, Becker G. p16/MTS1 inactivation in ovarian carcinomas: high frequency of reduced protein expression associated with hyper-methylation or mutation in endometrioid and mucinous tumors. Int J Cancer 1998 79 : 61 5.
12. Havrilesky LJ, Alvarez AA, Whitaker RS, Marks JR, Berchuck A. Loss of expression of the p16 tumor suppressor gene is more frequent in advanced ovarian cancers lacking p53 mutations. Gynecol Oncol 2001 83 : 491 500.
13. Suh SI, Cho JW, Baek WK, Suh MH, Carson DA. Lack of mutation at p16INK4A gene but expression of aberrant p16INK4A RNA transcripts in human ovarian carcinoma. Cancer Lett 2000 153 : 175 82.
14. Makarla PB, Saboorian MH, Ashfaq R et al. Promoter hypermethylation profile of ovarian epithelial neoplasms. Clin Cancer Res 2005 11 : 5365 9.
15. Katsaros D, Cho W, Singal R et al. Methylation of tumor suppressor gene p16 and prognosis of epithelial ovarian cancer. Gynecol Oncol 2004 94 : 685 92.
16. Debniak T, Scott RJ, Huzarski T et al. CDKN2A common variants and their association with melanoma risk: a population-based study. Cancer Res 2005 65 : 835 9.
17. McCloud JM, Sivakumar R, Greenhough A. et al. p16INK4a polymorphism: associations with tumour progression in patients with sporadic colorectal cancer. Int J Oncol 2004 25 : 1447 52.
18. Miller SA, Dybes DD, Polesky HF. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 1988 16 : 1215.
19. Sauroja I, Smeds J, Vlaykova T et al. Analysis of G(1)/S checkpoint regulators in metastatic melanoma. Genes Chromosomes Cancer 2000 28 : 404 14.
20. Conne B, Stutz A, Vassalli JD. The 3′ untranslated region of messenger RNA: a molecular 'hotspot' for pathology? Nat Med 2000 6 : 637 41.
21. Aitken J, Welch J, Duffy D et al. CDKN2A variants in a population-based sample of Queensland familial with melanoma. J Natl Cancer Inst 1999 91 : 446 52.
22. Geddert H, Kiel S, Zotz RB et al. Polymorphism of p16 INK4A and cyclin D1 in adenocarcinomas of the upper gastrointestinal tract. J Cancer Res Clin Oncol 2005 131 : 803 8.
23. Zheng Y, Shen H, Sturgis EM et al. Haplotypes of two variants in p16 (CDKN2/MTS-1/INK4a) exon 3 and risk of squamous cell carcinoma of the head and neck: a case-control study. Cancer Epidemiol Biomarkers Prev 2002 11 : 640 5.
24. Ichikawa Y, Yoshida S, Koyama Y et al. Inactivation of p16/CDKN2 and p15/MTS2 genes in different histological types and clinical stages of primary ovarian tumors. Int J Cancer 1996 69 : 466 70.
25. Scully RE. Histological typing of ovarian tumor, 2nd edn. Berlin, Germany : Springer, 1999 : 3 44.
26. Ono K, Tanaka T, Tsunoda T. Identification by cDNA microarray of genes involved in ovarian carcinogenesis. Cancer Res 2000 60 : 5007 11.
27. Spurdle AB, Webb PM, Purdie DM, Chen X, Green A, Chenevix-Trench G. Polymorphisms at the glutathione S-transferase GSTM1, GSTT1 and GSTP1 loci: risk of ovarian cancer by histological subtype. Carcinogenesis 2001 22 : 67 72.
28. Yang CQ, Chan KY, Ngan HY et al. Single nucleotide polymorphisms of follicle stimulating hormone receptor are associated with ovarian cancer susceptibility. Carcinogenesis 2006 27 : 1502 6.